GlassScriptPhysician profile
Ramya Krishna Rao
NPI 1336535699
$11,374.76
in general payments reported to CMS, 2019-2025
30 companies · $579 in 2025
The $579 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $260 · 2021: $1,927 · 2022: $2,217 · 2023: $3,617 · 2024: $1,489 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,414 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,414.23 |
| Education | $270.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,756.43 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $911.46 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $780.45 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $740.04 | 2019-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $735.04 | 2021-2024 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $621.89 | 2019-2024 | Winlevi, Absorica Ld, Ilumya |
| Galderma Laboratories, L.P. | $595.65 | 2019-2024 | Epsolay, Oracea, Aklief |
| Genzyme Corporation | $581.19 | 2019-2024 | |
| Amgen INC. | $411.40 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $373.76 | 2021-2024 | |
| Vyne Pharmaceuticals INC. | $370.83 | 2020-2021 | |
| Pfizer INC. | $300.57 | 2021-2024 | |
| Incyte Corporation | $296.88 | 2022-2024 | Opzelura |
| Mayne Pharma Commercial LLC | $272.60 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $266.76 | 2019-2024 | Jublia, Arazlo, Cabtreo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $235.03 | 2022-2025 | Cimzia, Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $158.89 | 2022-2023 | Valchlor |
| Journey Medical Corporation | $148.87 | 2021-2023 | |
| Prugen, INC. Pharmaceuticals | $140.00 | 2021 | |
| Arcutis Biotherapeutics, INC. | $109.81 | 2023-2024 | Zoryve |
| Almirall LLC | $107.23 | 2021-2023 | Seysara |
| Dusa Pharmaceuticals, INC. | $100.42 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $90.76 | 2022-2024 | Sotyktu |
| Epi Health, LLC | $54.59 | 2021-2022 | |
| Dermavant Sciences, INC. | $29.96 | 2022-2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.05 | 2023 | Spevigo |
| Merck Sharp & Dohme LLC | $24.74 | 2025 | Verquvo |
| Xeris Pharmaceuticals, INC. | $18.26 | 2025 | Keveyis |
| Medimetriks Pharmaceuticals, INC. | $16.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramya Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.